We are live on ! Find out more
VRDN icon

Viridian Therapeutics
VRDN

23 hedge funds and large institutions have $4.3M invested in Viridian Therapeutics in 2019 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.48% less ownership

Funds ownership: 2.33% → 1.85% (-0.48%)

30% less funds holding

Funds holding: 33 → 23 (-10)

46% less capital invested

Capital invested by funds: $7.95M → $4.3M (-$3.65M)

75% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 12

83% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 6

Holders
23
Holders Change
-10
Holders Change %
-30.3%
% of All Funds
0.45%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
3
Increased
1
Reduced
6
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$178K
2
WS
Wedbush Securities
California
+$60.3K
3
VF
Virtu Financial
New York
+$35.2K

Top Sellers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
-$1.01M
2
Goldman Sachs
Goldman Sachs
New York
-$152K
3
Millennium Management
Millennium Management
New York
-$151K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$150K
5
ARTA
A.R.T. Advisors
New York
-$16K

VRDN Hedge Fund Activity: Q4 2019 in Review

23 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q4 2019, worth a combined $4.3M — down 46% from $7.95M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of VRDN and 3 opened new positions — a net loss of 9 holders — while 6 trimmed existing stakes and 1 added.

The largest buyer was Renaissance Technologies, adding an estimated $178K. The largest seller was 683 Capital Management, cutting an estimated $1.01M.

  • 23 institutional investors held Viridian Therapeutics (VRDN) as of Q4 2019, down from 33 in Q3 2019.
  • Funds reported $4.3M of Viridian Therapeutics stock for Q4 2019, down 46% quarter-over-quarter.
  • 3 funds opened new Viridian Therapeutics positions in Q4 2019 and 12 closed out, a net change of -9 holders.
  • The largest Viridian Therapeutics buyer in Q4 2019 was Renaissance Technologies, an estimated $178K added.
  • The largest Viridian Therapeutics seller in Q4 2019 was 683 Capital Management, an estimated $1.01M sold.

Based on aggregated 13F filings for Q4 2019.